BRPI0407741B8 - pirimidinas e triazinas de inibição de replicação de hiv - Google Patents

pirimidinas e triazinas de inibição de replicação de hiv

Info

Publication number
BRPI0407741B8
BRPI0407741B8 BRPI0407741A BRPI0407741A BRPI0407741B8 BR PI0407741 B8 BRPI0407741 B8 BR PI0407741B8 BR PI0407741 A BRPI0407741 A BR PI0407741A BR PI0407741 A BRPI0407741 A BR PI0407741A BR PI0407741 B8 BRPI0407741 B8 BR PI0407741B8
Authority
BR
Brazil
Prior art keywords
hiv replication
triazines
replication inhibiting
inhibiting pyrimidines
pyrimidines
Prior art date
Application number
BRPI0407741A
Other languages
English (en)
Inventor
Therese Jeanne Pasquier Elisabeth
Bettens Eva
Frans Desiré Daeyaert Frederik
Maarten Vinkers Hendrik
Heeres Jan
Emile Georges Guillemont Jérôme
Hertogs Kurt
Maria Henricus Koymans Lucien
Rene De Jonge Marc
Adrian Jan Janssen Paul
Joannes Lewi Paulus
Original Assignee
Janssen R&D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R&D Ireland
Publication of BRPI0407741A publication Critical patent/BRPI0407741A/pt
Publication of BRPI0407741B1 publication Critical patent/BRPI0407741B1/pt
Publication of BRPI0407741B8 publication Critical patent/BRPI0407741B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

"pirimidinas e triazinas de inibição de replicação de hiv". esta invenção refere-se a inibidores de replicação de hiv de fórmula (i), seus n-óxidos, sais de adição farmaceuticamente aceitáveis, aminas quaternárias e formas estereoquimicamente isoméricas, seu uso como um medicamento, seus processos para preparação e composições farmacêuticas compreendendo os mesmos.
BRPI0407741A 2003-02-20 2004-02-20 pirimidinas e triazinas de inibição de replicação de hiv BRPI0407741B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03100411.2 2003-02-20
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
US60/475,012 2003-06-02
PCT/EP2004/050175 WO2004074261A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (3)

Publication Number Publication Date
BRPI0407741A BRPI0407741A (pt) 2006-02-14
BRPI0407741B1 BRPI0407741B1 (pt) 2018-05-29
BRPI0407741B8 true BRPI0407741B8 (pt) 2021-05-25

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0407741A BRPI0407741B8 (pt) 2003-02-20 2004-02-20 pirimidinas e triazinas de inibição de replicação de hiv
BRPI0407732-6A BRPI0407732A (pt) 2003-02-20 2004-02-20 pirimidinas e triazinas inibidoras da replicação de hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0407732-6A BRPI0407732A (pt) 2003-02-20 2004-02-20 pirimidinas e triazinas inibidoras da replicação de hiv

Country Status (27)

Country Link
US (2) US7442705B2 (pt)
EP (2) EP1597238B1 (pt)
JP (2) JP4586013B2 (pt)
KR (2) KR20050099994A (pt)
CN (2) CN1751031B (pt)
AP (1) AP2005003373A0 (pt)
AR (2) AR044499A1 (pt)
AT (2) ATE506353T1 (pt)
AU (2) AU2004213187B2 (pt)
BR (2) BRPI0407741B8 (pt)
CA (2) CA2516589C (pt)
CL (2) CL2004000303A1 (pt)
CY (1) CY1106788T1 (pt)
DE (2) DE602004006383T2 (pt)
DK (1) DK1597238T3 (pt)
EA (2) EA011256B1 (pt)
ES (1) ES2287734T3 (pt)
HR (2) HRP20050821A2 (pt)
IL (2) IL169596A (pt)
MX (2) MXPA05008867A (pt)
MY (1) MY138308A (pt)
NO (2) NO20054311L (pt)
NZ (2) NZ541601A (pt)
PL (2) PL226954B1 (pt)
PT (1) PT1597238E (pt)
TW (2) TW200510339A (pt)
WO (2) WO2004074261A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
EP1809614B1 (en) 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
EA020749B1 (ru) * 2006-12-29 2015-01-30 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5,6-замещенные пиримидины
DK2114901T3 (da) * 2006-12-29 2014-06-30 Janssen R & D Ireland Hiv-inhiberende 6-substituerede pyrimidiner
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2344458A1 (en) 2008-09-11 2011-07-20 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
EP2406253B1 (en) 2009-03-11 2013-07-03 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2018019204A1 (zh) 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
FI3966207T3 (fi) 2019-05-10 2023-11-30 Deciphera Pharmaceuticals Llc Autofagian fenyyliaminopyrimidiiniamidi-inhibiittoreita ja menetelmiä niiden käyttämiseksi
ES2962852T3 (es) 2019-05-10 2024-03-21 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de los mismos
CN114258318A (zh) 2019-06-17 2022-03-29 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
TR200002760T2 (tr) * 1998-03-27 2000-12-21 Janssen Pharmaceutica N.V. HIV engelleyici pirimidin türevleri
CN1214013C (zh) * 1998-11-10 2005-08-10 詹森药业有限公司 抑制hiv复制的嘧啶类
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ES2258018T3 (es) * 1999-09-24 2006-08-16 Janssen Pharmaceutica N.V. Dispersiones solidas antivirales.
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
AU2002216650A1 (en) 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1479397E (pt) * 2002-02-05 2011-09-01 Astellas Pharma Inc Derivados de 2,4,6-triamino-1,3,5-triazina
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
CA2490888C (en) * 2002-06-28 2011-05-24 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxamide derivative
ATE451104T1 (de) * 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
DE602004006383D1 (de) 2007-06-21
CA2516699C (en) 2011-07-12
NZ541601A (en) 2007-09-28
CL2004000306A1 (es) 2005-04-08
JP4586014B2 (ja) 2010-11-24
AU2004213186B2 (en) 2009-10-01
US20060194804A1 (en) 2006-08-31
MXPA05008866A (es) 2005-10-05
IL169647A0 (en) 2007-07-04
AU2004213187B2 (en) 2009-11-05
EP1603887A1 (en) 2005-12-14
DE602004006383T2 (de) 2008-01-10
IL169596A (en) 2017-02-28
AU2004213186A1 (en) 2004-09-02
EA200501326A1 (ru) 2006-02-24
KR20050099994A (ko) 2005-10-17
BRPI0407741B1 (pt) 2018-05-29
CN1751030A (zh) 2006-03-22
EA010423B1 (ru) 2008-08-29
BRPI0407741A (pt) 2006-02-14
IL169647A (en) 2013-05-30
JP4586013B2 (ja) 2010-11-24
AU2004213187A1 (en) 2004-09-02
CA2516589A1 (en) 2004-09-02
HRP20050820A2 (en) 2006-11-30
PL378136A1 (pl) 2006-03-06
CY1106788T1 (el) 2012-05-23
PL226954B1 (pl) 2017-10-31
PT1597238E (pt) 2007-08-08
NO20054312L (no) 2005-11-16
AP2005003373A0 (en) 2005-09-30
AR044499A1 (es) 2005-09-14
US20060142571A1 (en) 2006-06-29
CN1751031A (zh) 2006-03-22
CA2516589C (en) 2012-04-17
MY138308A (en) 2009-05-29
KR20050094896A (ko) 2005-09-28
NO20054312D0 (no) 2005-09-19
HRP20050821A2 (en) 2006-11-30
US7585870B2 (en) 2009-09-08
PL378064A1 (pl) 2006-02-20
EP1597238B1 (en) 2007-05-09
IL169596A0 (en) 2007-07-04
CN1751031B (zh) 2010-07-21
CN100572364C (zh) 2009-12-23
NZ542428A (en) 2007-11-30
EA011256B1 (ru) 2009-02-27
US7442705B2 (en) 2008-10-28
ATE506353T1 (de) 2011-05-15
EP1597238A1 (en) 2005-11-23
EP1603887B1 (en) 2011-04-20
WO2004074261A1 (en) 2004-09-02
JP2006518356A (ja) 2006-08-10
DK1597238T3 (da) 2007-09-10
MXPA05008867A (es) 2005-10-05
AR044500A1 (es) 2005-09-14
ATE361915T1 (de) 2007-06-15
NO20054311L (no) 2005-10-27
TW200500346A (en) 2005-01-01
EA200501327A1 (ru) 2006-02-24
TW200510339A (en) 2005-03-16
JP2006518357A (ja) 2006-08-10
BRPI0407732A (pt) 2006-02-14
CL2004000303A1 (es) 2005-04-08
PL227295B1 (pl) 2017-11-30
DE602004032321D1 (de) 2011-06-01
WO2004074262A1 (en) 2004-09-02
CA2516699A1 (en) 2004-09-02
NO20054311D0 (no) 2005-09-19
ES2287734T3 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
BRPI0407741B8 (pt) pirimidinas e triazinas de inibição de replicação de hiv
BRPI0407306A (pt) 1,2,4- triazinas de inibição de hiv
BRPI0507065A (pt) derivados de quinolina e seu uso como inibidores micobacterianos
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
WO2001085700A3 (en) Hiv replication inhibiting pyrimidines and triazines
BR122015023612B8 (pt) compostos derivados de pirimidina, seu uso, composição farmacêutica e produto
PA8516501A1 (es) Profarmacos de pirimidinas inhibitorias de la replicacion de hiv
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
BRPI0414570A (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BRPI0414548A8 (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
BRPI0413469A (pt) derivados de piperazina para o tratamento de infecções por hiv
UY30183A1 (es) Derivados de quinolina
BR0317658A (pt) Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina substituìda e seu emprego como antagonistas de neuroquinina
BRPI0511999A (pt) compostos como antagonistas de ccr5
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
BRPI0417609B8 (pt) derivados de 3-ciano-quinolina com atividade antiproliferativa, seu processo de preparação e uso e composição farmacêutica que os compreende
BR112023016986A2 (pt) Compostos de aminopirimidina e métodos de seu uso
AR021137A1 (es) Derivados de triazina 2,4-disustituida, uso de los mismos para preparar medicamentos, composiciones farmacéuticas que los comprenden, procedimiento para prepararlas, y procedimiento para preparar dichos derivados.
BR112022007680A2 (pt) Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos
UA81654C2 (ru) Пиримидины и триазины, которые ингибируют репликацию вич

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/05/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2658 DE 14-12-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.